Cancer Research AACR Conference on Molecular Diagnostics - 2008  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 51, 3362-3366, July 1, 1991]
© 1991 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Utsumi, T.
Right arrow Articles by Klostergaard, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Utsumi, T.
Right arrow Articles by Klostergaard, J.

Preparation and Characterization of Liposomal-Lipophilic Tumor Necrosis Factor1

Toshihiko Utsumi, Mien-Chie Hung and Jim Klostergaard2

Department of Tumor Biology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

The liposomal delivery of recombinant human tumor necrosis factor (rHuTNF) has been shown to be effective in reducing its toxic effects and in its targeting of organs rich in cells of the reticuloendothelial system. However, native recombinant human TNF shows only poor affinity for liposomes, presumably due to its low hydrophobicity. In an attempt to increase the efficiency of association with liposomes, we have modified TNF to increase its hydrophobicity by selective substitution of its amino groups with fatty acid side chains. N-Hydroxysuccinimide esters of saturated fatty acids ranging from C8 to C18 were reacted with recombinant human TNF. Modification with esters of C8 to C14 acids occurred as determined by consumption of positively charged amino groups monitored by native polyacrylamide gel electrophoresis; however, esters of longer chain lengths (C16, C18) were much less capable of introducing these chains via amide linkages, and thus these adducts were not further characterized. Biological assays revealed that retention of activity was inversely dependent both on the number of chains introduced and on their length; activity was most conserved (>50%) in a TNF preparation modified with only ~1–2.5 caprylic acid (C8) residues/trimer. This preparation was found to bind with high efficiency (~50%) to preformed dipalmitoylphosphatidylcholine-small unilamellar vesicles. The extent of binding closely paralleled both the number of chains introduced and their length; binding was even more efficient (80–90%) for TNF modified either with ~3.5 caprylic acid residues/trimer or with ~1.5 residues of myristic acid (C14). However, the biological activity of these acylated TNFs was further reduced by this more extensive chemical modification (<50% activity for C8 and <10% for C14). The biological activity of dipalmitoylphosphatidylcholine-small unilamellar vesicle-C8-TNF was found to be comparable to that of the nonliposomal C8-TNF. Thus, biologically active preparations of liposomal-lipophilic TNF can be prepared with high efficiency.

1 Supported by American Cancer Society Grant IM-571.

2 To whom requests for reprints should be addressed, at Box 108, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030.

Received 12/ 4/90. Accepted 4/19/91.




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
N. S. Postma, D. J. A. Crommelin, W. M. C. Eling, and J. Zuidema
Treatment with Liposome-Bound Recombinant Human Tumor Necrosis Factor-alpha Suppresses Parasitemia and Protects against Plasmodium berghei k173-Induced Experimental Cerebral Malaria in Mice
J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 114 - 120.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1991 by the American Association for Cancer Research.